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Many of the molecular and pathological features associated with human Alzheimer
disease (AD) are mirrored in the naturally occurring age-associated neuropathology in
the canine species. In aged dogs with declining learned behavior and memory the
severity of cognitive dysfunction parallels the progressive build up and location of Aβ
in the brain. The main aim of this work was to study the biological behavior of soluble
oligomers isolated from an aged dog with cognitive dysfunction through investigating
their interaction with a human cell line and synthetic Aβ peptides. We report that
soluble oligomers were specifically detected in the dog’s blood and cerebrospinal fluid
(CSF) via anti-oligomer- and anti-Aβ specific binders. Importantly, our results reveal the
potent neurotoxic effects of the dog’s CSF on cell viability and the seeding efficiency
of the CSF-borne soluble oligomers on the thermodynamic activity and the aggregation
kinetics of synthetic human Aβ. The value of further characterizing the naturally occurring
Alzheimer-like neuropathology in dogs using genetic and molecular tools is discussed.
Keywords: canine cognitive dysfunction, Alzheimer, canine, Aβ oligomers, neuropathology, aggregation,
neurotoxicity
INTRODUCTION
Aging dogs spontaneously deposit human-type amyloid β (Aβ) peptide (Selkoe et al., 1987;
Johnstone et al., 1991) and thus are a natural higher mammalian model of aging. The canine Aβ
precursor protein (APP) is virtually identical to human APP (∼98% homology). In parallel with
progressive Aβ pathology, aged dogs show decline in measures of learning and memory that are
correlated with the extent and location of Aβ (Cotman and Head, 2008). However, a recent report
by Borghys and colleagues demonstrated that high levels of Aβ in the cerebrospinal fluid (CSF) of
young and middle-aged dogs correlated with impaired learning (Borghys et al., 2017), in contrast
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with previous reports showing that CSF Aβ content decreases
in the aged/aging dog (Head et al., 2010). Of note, cognitive
decline occurs prior to the accumulation of Aβ plaques in the
canine brain, suggesting that earlier assembly states of Aβ (e.g.,
oligomers, protofibrils) may be the toxic species in the canine
brain as in the human brain (Head et al., 2010).
In this study, we describe the presence of Aβ soluble oligomers
in serum and CSF of a 12-year-old Samoyed (referred to
as “the Subject” throughout this report). Upon neurological
examination, this subject displayed signs of cognitive impairment
and magnetic resonance imaging (MRI) showed diffuse cortical
atrophy. Aβ immunostaining demonstrated extensive diffuse
plaques in the neocortex and hippocampal regions; but no
tau staining. Of importance, CSF and serum from this subject
exhibited neurotoxic effects following treatment of a human
neuroblastoma cell line and led to efficient aggregation of
synthetic human Aβ peptides.
CASE REPORT
Ethics Statement
This project was reviewed by the University of Surrey Ethics
Committee and verified that the aspects of the study pertaining
FIGURE 1 | MR imaging of cortical atrophy and myelin degeneration. (A) Mid-sagittal T2W image of the brain demonstrating atrophy of the intra-thalamic adhesion (*)
height 4.76mm. (B) Transverse T2W at the level of temporal lobes demonstrating cortical atrophy with widening of the subarachnoid space (green arrow) and
enlargement of the lateral ventricle (orange arrow). (C) Transverse FLAIR at level of temporal lobes and (D) transverse FLAIR at level of occipital lobes and midbrain
demonstrating white matter hyperintensity (blue arrows).
to the Samoyed dog including use of body fluids excess
and post mortem material did not come under the auspices
of Animals (Scientific Procedures) Act 1986 (ASPA). The
subject’s owner gave informed consent to participation
in the study. Full clinical and neurological examination
and presentation, including MR imaging assessment are
found in Supplementary Materials. Negative control CSF
was obtained from a 10-year-old male Rottweiler suffering
from nodular granulomatous episclerokeratitis following
submission for routine teaching post-mortem and not subject
to animal ethics guidelines. CSF derived from a 79-year-old
patient with advanced sporadic AD (pos1-CSF) and from
a 65 year old patient with advanced sporadic AD (pos2-
CSF) were provided by The UK Multiple Sclerosis Tissue
Bank.
Clinical Presentation
A 12-year-old neutered male Samoyed dog was presented
for pain management and evaluation of difficulty in rising.
Neurological examination revealed tetraparesis and reduced
spinal reflexes andmuscle tone consistent with a polyneuropathy.
The difficulty rising was attributed to this, complicated by
the sedative polypharmacy. The historical and consulting
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room behavior suggested a cognitive function deficit possibly
complicated by a urinary tract infection. The brain MRI scan
revealed a diffuse cortical atrophy and a hyperintensity in
the white matter on T2W, particularly in the corona radiata
(Figure 1); changes consistent with age-associated cognitive
decline (Hasegawa et al., 2005). Signs were controlled for
the next 6 months after which the dog deteriorated and
described as being extremely agitated and distressed during
the night which was unresponsive to changing dose of
medication and resulting in significant sleep deprivation for
the owners. A full post mortem examination was undertaken
at the pathology facility at the University of Surrey and the
brain and other organs were removed for further analysis.
A more extensive description of the clinical and neurological
examination and presentation is included as supplementary
results.
Detection of Aβ Species in the Subject’s
Serum, CSF, and Brain
Neuronal loss and degeneration was marked in the cortical
region of the subject (Figures 2A,B) while intense binding
of large extra-cellular diffuse Aβ plaques, recruitment, and
activation of astrocytes and microglial cells (Figures 2C–E)
were observed in the neocortex and hippocampus. Pronounced
cerebral amyloid angiopathy (CAA) was observed in several
cortical blood vessels (Figure 2F), but was less intense in
the tunica media of leptomeningeal arteries. Of note, PHF
and the signaling adapter p62 were not detected (data not
shown) (Babu et al., 2005). Furthermore, white matter
degeneration took the form of myelin vacuolation and
isomorphic gliosis (Figure 2A) with macrophages containing
pale yellow cytoplasmic material evident as small clusters
of cells and as perivascular aggregates (Figure 2A). Iba1
FIGURE 2 | Cortico-neuropathological microscopic lesions. (A) Cortical degeneration (vacuolation) and neuronal death observed on routine H&E stained sections of
prefrontal cortex and diffuse cerebral periventricular white matter degeneration (vacuolation and pallor); (B) Neuronal degeneration and loss (arrows) confirmed with
neuron-specific marker, NeuN. (C) Specific labeling of diffuse Aβ plaques with anti-Aβ specific antibody in the prefrontal cortex. (D) Extensive gliosis in prefrontal
cortex revealed by GFAP stain and associated with (E) microglia activation demonstrated with Iba1 staining. (F) Specific labeling of CAA with anti-Aβ specific antibody
in the cortical blood vessels in the prefrontal cortex.
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FIGURE 3 | Immuno-detection of Aβ soluble oligomers. (A) Western blot
showing the ability of PRIOC10 anti-oligomer antibody to strongly
immunocapture precipitates from the CSF (sub-CSF) but not the serum
(sub-serum) derived from the dog. Positive control derived from CSF from
Alzheimer’s disease patients (patient case number 51486—age 79 years
[pos1-CSF] and 60649–65 years [pos2-CSF]) displayed PRIOC10-positivity for
soluble oligomers. In contrast, CSF (neg-CSF) and serum (neg-serum) derived
from a Rottweiler failed to display PRIOC10 labeling on Western blotting. (B) A
customized Sandwich ELISA was used to detect specific Aβ oligomers.
Biotinylated anti-Aβ 4G8 (Aβ) (Thakker et al., 2009), PrioAD12 (Aβ1–40) or
PrioAD13 (Aβ1–42) (David et al., 2014) were used to immunocapture Aβ
species contained in the CSF (sub-CSF) and the serum (sub-serum)
precipitates derived from the dog. Purified PRIOC10 anti-oligomer antibody
was added to immunodetect specifically Aβ soluble oligomers. The sandwich
format of the assay has established the specificity of PRIOC10 antibody for Aβ
oligomers. Values shown are the mean Aβ ± SD from 12 observations.
stain demonstrated more widespread microglial/macrophage
activation while GFAP confirmed the brisk gliosis (data not
shown).
The ability of PRIOC10 mAb to bind to Aβ soluble oligomers
in sub-serum and sub-CSF was assessed by Western blotting
and Sandwich ELISA. Western blotting results indicate that
PRIOC10 mAb bound to soluble oligomers in sub-CSF but not
in sub-serum or negative control CSF (neg-CSF) derived from
the Rottweiler (Figure 3A). Further, PRIOC10 mAb pattern of
recognition revealed several bands ranging between 50 and 160
kDa (Figure 3A); and positive control CSF (pos-CSF) isolated
from two patients with AD also led to detection of soluble
oligomers (Figure 3A).
We then set out to investigate the specificity of the soluble
oligomers and confirm that the PRIOC10-specific bands detected
in the sub-CSF were mainly composed of Aβ using our
customized sELISA as described previously (Tayebi et al.,
2011). PRIOC10, 4G8 (Aβ) (Thakker et al., 2009), PrioAD12
(Aβ1–40), or PrioAD13 (Aβ1–42) (David et al., 2014) were
used as immunocapture antibodies to detect soluble oligomers
in the sub-CSF and sub-serum, followed by immunodetection
with biotinylated PRIOC10 (Figure 3B). We show that the
4G8 vs. biot-PRIOC10 combination detected highest levels of
Aβ in sub-CSF as expressed in OD-values (p = 0.0001) and
almost matched CSF levels detected with the PRIOC10 vs. biot-
PRIOC10 combination. This was followed by the PRIOAD13
vs. biot-PRIOC10 combination that displayed higher CSF levels
of detection compared with the PRIOAD12 vs. biot-PRIOC10
combination (p = 0.0279). Of note, sELISA lead to detection
of Aβ in the sub-serum (Figure 3B) in contrast with western
blotting, albeit with significantly lower OD intensity as compared
to levels detected in the sub-CSF.
Mutations in Presenilin 1, Presenilin 2, and
Amyloid Precursor Protein Genes Were Not
Identified
Genome assembly CanFam3.1 and transcripts
ENSCAFT00000013599.4 for APP, ENSCAFT00000026626.1 for
PSEN1, and ENSCAFT00000025451.3 for PSEN2 were used for
primer design (See Supplementary Results: Table S2) and as the
reference for sequence analysis. The subject’s DNA was used to
sequence the genes that when mutated are known to cause AD in
humans. No variants expected to be pathogenic were identified.
Synonymous variants were found in APP (p.G120G; p.K178K;
p.A242A; p.T266T), and PSEN2 (p.P436P).
CSF and Serum Derived from Subject Was
Toxic to Neuron-Like SH-SY5Y Cell Line
The toxic effects of monoAβ1–40, monoAβ1–42, scramAβ25–35,
oligoAβ1–40, oligoAβ1–42, fibAβ1–40, fibAβ1–42, sub-serum,
and sub-CSF on differentiated human neuroblastoma cell
line RA-SH-SY5Y viability was investigated using the MTT
assay. To achieve similar concentrations of synthetic Aβ and
CSF/serum-borne Aβ, standard curves of all synthetic Aβ was
generated and the subject’s CSF and serum Aβ oligomers values
were determined by comparison to the appropriate standard
curve. MonoAβ1–40, monoAβ1–42, scramAβ25–35, and sub-
serum displayed no toxicity toward RA-SH-SY5Y neuroblastoma
cells as compared to untreated cells (p ≤ 0.05) (Figure 4). In
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contrast, treatment with oligoAβ1–40, oligoAβ1–42, fibAβ1–40,
fibAβ1–42, and sub-CSF lead to significant cell death as compared
with untreated cells, resulting in≤61% cell viability for treatment
with both oligoAβ1–40 and fibAβ1–40 (p ≤ 0.05) and ≤44% cell
viability for treatment with oligoAβ1–42, fibAβ1–42, and sub-CSF
(p ≤ 0.05) (Figure 4).
Cell viability was significantly affected following treatment
with oligoAβ1–42 compared with treatment with the fibrillary
species of Aβ1–42 (17 vs. 27%; p ≤ 0.05), while treatment with
sub-CSF lead to 44% cell death. These results show that the
subject’s CSF induced RA-SH-SY5Y cell death and confirmed the
potent toxic effects of Aβ soluble oligomers previously shown to
affect neurons (Bate et al., 2008).
CSF but Not Serum Derived from the
Subject Accelerates Aβ Aggregation
Kinetics in Vitro
We first demonstrated that PRIOC10 immunodetected Aβ
soluble oligomer species derived from monoAβ1–40 and
monoAβ1–42 peptides (Figure 5A). Secondly, ThT fluorescence
intensity of the fibrilar species was measured following
conversion of monoAβ1–40, monoAβ1–42, and scramAβ25–35
peptides was assessed and was shown to be inversely proportional
to levels of PRIOC10-specific oligomer species (Figure 5B).
ThT did not bind to scramAβ25–35 peptide before and after
being incubated in conversion buffer and to monoAβ1–40 and
monoAβ1–42 peptides before conversion. Of note and as shown
previously, PRIOC10 failed to bind the fibrilar species (Tayebi
et al., 2011).
We then assessed aggregation kinetics of “seed-free” synthetic
monomeric Aβ peptide following addition of Aβ oligomers or
fibrils (Figures 5C,D). A known concentration of Aβ prepared
by conversion during 12 h (t12) and 72 h (t72), as described
above, was used in the seeding reaction; as t12 represents
maximal optical density (OD) expression of Aβ soluble oligomers
immunodetected with PRIOC10 (Figure 5A) and t72 represents
maximal fluorescence expression of Aβ fibrils bound to ThT
(Figure 5B).
Here, we added 10 pmol oligoAβ1–40/oligoAβ1–42 (t12),
fibAβ1–40/fibAβ1–42 (t72), or scramAβ25–35 (t12 and t72)
prepared by conversion during t12 and t72 to 2mMmonoAβ1–40,
or monoAβ1–42 in order to assess their effects on the “lag-
phase” kinetic as measured by ThT fluorescence. We report
that t12 oligoAβ1–40, oligoAβ1–42 but not post-conversion
scramAβ25–35 led to substantial reduction of the “lag-
phase” (p ≤ 0.05) compared to t0 Aβ (Figures 5C,D).
Importantly, we show that oligoAβ1–42 was more efficient
in shortening the “lag-phase” compared to oligoAβ1–40 (p
≤ 0.05). Both t72 fibAβ1–40 and fibAβ1–42 but not post-
conversion scramAβ25–35 affected the Aβ aggregation kinetic
by shortening the reaction’s “lag-phase,” albeit the effect was
limited when compared to the addition of the oligomers
(Figures 5C,D), reflecting a weaker seeding ability of the
fibrils.
Finally, the subject’s serum and CSF was added to “seed-
free” synthetic monomeric Aβ to investigate whether pre-existing
FIGURE 4 | CSF but not serum derived from the aged dog leads to
neurotoxicity of neuron-like SH-SY5Y cell line. The effect of CSF and serum on
the survival of SH-SY5Y cell line was compared with monoAβ1–40,
monoAβ1–42, scramAβ25–35, oligoAβ1–40, oligoAβ1–42, fibAβ1–40, fibAβ1–42
as well as CSF (neg-CSF) and serum (neg-serum) derived from a Rottweiler.
Values shown are the mean cell survival ± SD from 12 observations.
oligomer seeds contained in the serum and CSF of the aged
dog can affect the Aβ aggregation kinetics through reduction
of the “lag-phase” and to explore if cross-species interaction
of dog Aβ with human Aβ synthetic peptide overcomes the
so-called “species barrier” as applies for prion disorders (Hill
and Collinge, 2002). First, we tested whether the precipitation
protocol altered the conformation of Aβ soluble oligomer content
of sub-CSF and sub-serum. We show that PRIOC10-specific
Aβ oligomers in TCA/acetone treated sub-CSF and sub-serum
were preserved (Figure S1). Total protein (20 µl of 10 mg/ml)
derived from sub-serum and sub-CSF samples were incubated
with solutions of monoAβ1–40, and monoAβ1–42 peptides.
Surprisingly and for the first time, we show that the dog’s CSF
led to a substantial shortening of the reaction’s “lag-phase” (p ≤
0.05) and acceleration of human synthetic monomeric Aβ1–40
and Aβ1–42 aggregation as compared to a negative control CSF
derived from the Rottweiler or scramAβ25–35 (Figures 5E,F).
Sub-CSF was more efficient in speeding up Aβ1–42 then Aβ1–40
aggregation. In contrast, sub-serum and negative control serum
led to complete inhibition of the Aβ kinetics and the “lag-phase”
was not observed (Figures 5E,F). Of note, similar concentrations
of synthetic Aβ and CSF/serum-borne Aβ were used.
DISCUSSION
The neuropathological changes observed in the 12-year-old
Samoyed dog were previously described in aged dogs (Youssef
et al., 2016). The extra-cellular diffuse Aβ deposits were observed
throughout the cerebral cortex I-IV layers adhering to the
typical staged distribution recognized in cognitively impaired
dogs (Pugliese et al., 2006) and human AD (Schmidt et al., 2015).
Several blood vessels of the cerebral cortex displayed severe
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FIGURE 5 | Aggregation kinetics of “seed-free” synthetic monomeric Aβ peptide. Synthetic seed-free Aβ monomers were used to produce (A) PRIOC10-labeled Aβ
soluble oligomers and (B) Aβ ThT-labeled fibrils in a kinetic reaction (0–72 h). t0 is the initial time just before starting the kinetic reaction (t0 = seed-free monomers
only); t12 represents maximal OD value of PRIOC10-specific Aβ oligomers (t12 = maximal oligomer yield); and t72 represents maximal value of ThT-specific Aβ fibrils
(t72 = maximal fibrils yield). (C) seed-free Aβ1–40 (t0) aggregation kinetic was assessed after addition of known quantities of preformed Aβ1–40 amyloid seeds (t12
and t72) and compared with the aggregation kinetic after addition of conversion buffer or scrambled Aβ25–35 (t12 and t72). (D) seed-free Aβ1–40 (t0) aggregation
kinetic was assessed after addition of known quantities of preformed Aβ1–42 amyloid seeds (t12 and t72) and compared with the aggregation kinetic after addition of
conversion buffer or scrambled Aβ25–35 (t12 and t72). (E) seed-free Aβ1–40 (t0) aggregation kinetic was assessed after addition of known quantities of sub-CSF and
sub-serum and compared with the aggregation kinetic after addition of conversion buffer, negative control CSF (neg-CSF) or serum (neg-serum). (F) seed-free Aβ1–42
(t0) aggregation kinetic was assessed after addition of known quantities of sub-CSF and sub-serum and compared with the aggregation kinetic after addition of
conversion buffer, negative control CSF (neg-CSF) or serum (neg-serum). Error bars represent the mean level derived from n = 4 wells.
and pronounced CAA. Colle et al. have previously shown that
Aβ1–42-positive and Congo red-Aβ1–40-negative deposits were
predominant in the brain parenchyma of aged dogs while Aβ1–40
deposited to the vasculature (Colle et al., 2000). White matter
degeneration was also evident in our aged dog with vacuolation
of myelinated tracts, accumulation of what appears to be
lipofuscin-filled macrophages as perivascular aggregates and
widespread microglial activation and gliosis. In human AD, the
significance of white matter degeneration remains in dispute as
its significance in disease pathogenesis remains uncertain (Ihara
et al., 2010) mainly because these are considered as geriatric
changes and recognized in cognitively normal individuals and
dogs (Lintl and Braak, 1983; Chambers et al., 2012). Notably, in
our behaviorally impaired dog, we have not been able to detect
APP, PSEN1, or PSEN2 gene autosomal dominant mutations
which are known to directly influence accumulation of Aβ
plaques and CAA in human AD (Selkoe, 2001).
In human AD, Aβ soluble oligomers are considered the
neurotoxic species with the ability to affect cognitive ability
and alter synaptic functions (Selkoe, 2002). Attempts to detect
putative relatively low amount of CSF- and serum-borne Aβ
soluble oligomers in AD patients have been hampered by
the lack of assays with sufficient sensitivity and specificity
(Bruggink et al., 2013; Herskovits et al., 2013; Hölttä et al.,
2013; Tai et al., 2013; Savage et al., 2014). The importance of
Aβ soluble oligomers in the pathogenesis of cognitive deficits
and their effects on synaptic activity and function have not been
investigated in aged dogs with cognitive deficits; however a report
by Head et al. demonstrated that levels of CSF-borne Aβ soluble
oligomers correlated inversely with total brain amounts of Aβ
in aged beagles (Head et al., 2010). However, a recent report
by Borghys et al. showed that high levels of Aβ in the CSF
of young and middle-aged dogs were detected and correlated
with impaired learning (Borghys et al., 2017). The report does
not specify whether Aβ measured in the CSF of these animals
contains soluble oligomer species (Borghys et al., 2017). We
have shown here that our anti-oligomer antibody displayed
oligomer-specific bands ranging from 90 to 200 kDa in the
CSF but not in serum derived from the behaviorally impaired
dog, the latter probably reflecting low levels of Aβ soluble
oligomer concentrations in blood (Santos et al., 2008). Similarly,
Aβ was detected with our two-site sELISA in CSF; using
PRIOC10 as immunocapture antibody and a biotinylated anti-
Aβ (4G8), anti-Aβ1–40 (PrioAD12), or anti-Aβ1–42 (PrioAD13)
for immunodetection, and further confirms the Aβ specificity
of the soluble oligomers observed on western blotting. Of
importance, the sELISA detected significantly higher levels of
total Aβ oligomers (PRIOC10 vs. 4G8), followed by Aβ1–42
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soluble oligomers (PRIOC10 vs. PRIOAD13 combination) then
Aβ1–42 soluble oligomers (PRIOC10 vs. PRIOAD12). In contrast
with the result observed on Western blotting, we were able to
detect soluble oligomers in the serum of our aged dog, albeit the
levels were much lower than those observed in the CSF. Taken
together, these results demonstrate the presence of different
species of Aβ soluble oligomers in the subject’s CSF in agreement
with the results reported by Head et al. (2010). The results also
confirm the “hierarchy” of Aβ1–42 over Aβ1–40 as observed in
human AD (Armstrong, 2014).
We then set out to investigate the toxic nature of CSF- and
serum-borne Aβ species derived from our behaviorally impaired
dog by treating a neuron-like cell line and compare their effects
with synthetic Aβ oligomers and fibrils derived from synthetic
monomeric Aβ1–40 and Aβ1–42. Surprisingly, CSF but not serum
derived from our behaviorally impaired dog significantly affected
cell viability as measured by MTT. Several studies have reported
that soluble oligomers accumulate in the CSF of AD patients and
exhibit putative neurotoxic effects of homologous Aβ in vitro
(Bate and Williams, 2007; Shankar et al., 2007; Bate et al., 2008).
To our knowledge, this is the first report showing that CSF-borne
Aβ oligomers from a dog with behavioral impairment affected
viability of human-derived neuron-like cell lines; further proving
the potent neurotoxic effects of Aβ soluble oligomers, although
other factors might be implicated in the observed toxic effect.
The impact on cell viability of the CSF was compared to synthetic
Aβ1–40 and Aβ1–42 oligomers and fibrils following treatment of
the neuroblastoma cell line; CSF was shown to be more toxic
than either Aβ1–40 oligomers and fibrils but expectedly less so
than Aβ1–42 oligomers and fibrils. This is similar to our previous
results showing that Aβ1–42 was more potent at damaging
neuronal synapses compared with Aβ1–40 peptide (Bate et al.,
2008). It is important to note that the oligomeric/fibrillar Aβ
content of the CSF derived from the behaviorally impaired dog
is not known, hence a more accurate comparison can only
be achieved through subjecting the cells to similar and known
concentration of Aβ species in biological fluids.
A central feature in AD is fibril biogenesis leading to senile
plaques (Powers and Powers, 2008). The molecular mechanism
underlying the formation of fibrils controls the speed and the
degree of its formation and the kinetics of oligomers and
protofibrils (Jarrett and Lansbury, 1993; Caughey and Lansbury,
2003) and directly influences AD pathogenesis. Here, we
investigated the seeding efficiency of CSF- and serum-borne Aβ
oligomers and their influence on human synthetic Aβ peptides.
Initially, we established assay conditions and reproducibility by
adding known concentrations of post-conversion t12-Aβ and t72-
Aβ oligomers and fibrils into the reaction. As anticipated, we
show that all forms of post-conversion Aβ, except scrambled
Aβ25–35 peptide, led to a substantial reduction of the lag
phase (oligoAβ1–42 > oligoAβ1–40 > fibAβ1–42 ≥ fibAβ1–40).
Following addition of CSF derived from our behaviorally
impaired dog, the Aβ aggregation kinetic was substantially
altered and led to reducing the lag phase, confirming both the
presence but also the potent effect of soluble oligomers. In
contrast, serum, negative control CSF and scrambled Aβ25–35
peptide did not affect the kinetic of the reaction. The ability
of CSF-borne soluble oligomer to affect synthetic peptides
derived from human β sequences was perhaps expected as
the canine APP shares about 98% homology with human
APP. Nevertheless, this result is important as it demonstrates
inter-species molecular interaction but does not suggest nor
does it demonstrate any interspecies transmission between
humans and dogs. Finally, studies are underway to determine
whether the above findings are a more universal phenomenon
recognized in different breeds of aged and behaviorally impaired
dogs.
CONCLUDING REMARKS
We have comprehensively demonstrated that this behaviorally
impaired dog exhibited Aβ and Aβ soluble oligomers in its
blood, CSF, and brain. We also show that the dog’s Aβ affects
the survival of human-derived neuron-like cell line and has
a direct effect on the aggregation kinetics of human synthetic
Aβ peptides. The study failed to demonstrate the involvement
of phospho-tau and more genetic and molecular studies are
needed to decipher its role in the neuropathology underlying
cognitive dysfunction, yet we would advocate that dogs with
behavioral impairments should be studied and the disease
mechanisms investigated in a similar fashion as is the case
with AD.
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